Novartis signed two different separate licensing agreements with two development-stage firms, Bluebird (BLUE) and Celyad (CYAD). The signing of the agreements, enabled Novartis to license the two firm’s proprietary technologies, both related to improving Novartis’ genetically engineered immunooncology CAR- T cells.
The Celyad/Novartis Agreement
Celyad announced a non-exclusive license agreement with Novartis for its US patents issued for the production of allogeneic CAR-T cells. This license agreement is related to two targets currently under development by Novartis. The agreement includes Celyad’s intellectual property . . .